The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSun Yat-sen University
About this trial
Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage. However, whether patients could benefit from the ablation for intermediate recurrent HCC (RHCC) is still need high quality clinical evidence. This study is to evaluate the efficacy of ablation combined with TACE and Lenvatinib for the intermediate-stage RHCC.
Eligibility criteria
Qualifiers
18-75 years;
RHCC diagnosed by imaging;
intermediate-stage RHCC (two to three lesions which at least one was >3 cm in size or more than three tumors);
the tumor number was no more than six, and the maximum tumor diameter was ≤5 cm;
Disqualifiers
under 18 years or over 75 years of age;
primary intermediate-stage HCC;
RHCC with more than six tumors, or single RHCC
Trial design
Treatments tested in this trial
- TACE
- Ablation
- Lenvatinb
Treatment groups
116 Participants
are divided into 2 treatment groupsSponsors and collaborators
Sun Yat-sen University
Lead sponsor
Chinese PLA General Hospital
Collaborator
Source ClinicalTrials.gov